Navigation Links
Unilens Vision Reports Record First Quarter Earnings and Royalty Income
Date:11/29/2007

First Quarter Net Income Increases 22% and Royalty Income Increases 29%

From Prior Year

LARGO, Fla., Nov. 29 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF) (TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the first quarter of FY2008.

Net sales, excluding royalty income, for the quarter ended September 30, 2007 increased to $1,673,361 compared with $1,604,776 in the quarter ending September 30, 2006, an increase of 4.3%. The increase was primarily the result of continued growth of the Company's C-Vue multifocal contact lenses, which increased approximately 11% in the current quarter, which was partially offset by sales of our replacement products lines that declined as expected.

Net Income for the quarter increased 22% to a record first quarter of $377,296, or $0.08 per diluted share, compared with $310,492, or $0.07 per diluted share in the prior-year period.

Royalty income for the quarter increased 28.6% to a record first quarter of $612,799 compared with $476,550 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to accelerate, resulting in the record quarterly royalty.

Income before taxes for the quarter ended September 30, 2007 increased 20% to $616,501, compared with $515,183 in the prior-year quarter. After recording income tax expense of $239,205, Unilens reported net income of $377,296, or $0.08 per diluted share. In the first quarter of FY2007, the Company reported net income of $310,492, or $0.07 per diluted share, after recording income tax expense of $204,691.

"We are pleased with our first quarter operating results and are optimistic regarding the outlook for our operating results for the remainder of the current fiscal year," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc., "Sales of our C-Vue disposable multifocal lenses continues to increase as well as the license royalties from Bausch and Lomb which provides a healthy stream of profitable revenues."

"I am also pleased to report that we recently paid our regular quarterly cash dividend of $0.09 per share, in accordance with a dividend policy adopted by our Board of Directors that is intended to allow our shareholders to share directly in the Company's future earnings growth," concluded Mr. Pecora. The Company's regular quarterly cash dividend was paid on November 28, 2007 to shareholders of record at the close of business on November 14, 2007.

About Unilens Vision Inc. - "The Eye Care Professionals Specialty Contact Lens Company"

Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets specialty contact lenses under the C-Vue, Unilens, Sof-Form, Aquaflex, SoftCon, Lombart, and LifeStyle brands. Additional information on the Company may be accessed on the Internet at http://www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".

(Note: All financial information in this release is stated in U.S. Dollars.)

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward- looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531

UNILENS VISION INC.

FIRST QUARTER - FISCAL 2008

CONDENSED CONSOLIDATED FINANCIAL INFORMATION

(All figures in U.S. Dollars)

RESULTS OF OPERATIONS

Three Months Ended Three Months Ended

September 30, 2007 September 30, 2006

Sales $1,673,361 $1,604,776

Cost of sales 904,397 830,630

768,964 774,146

Expenses 754,952 752,707

Income from operations 14,012 21,439

Other items:

Royalty income 612,799 476,550

Other (expense) income (27,141) 990

Remeasurement income 2,541 3,377

Interest income 14,290 12,827

602,489 493,744

Income before tax 616,501 515,183

Income tax expense 239,205 204,691

Net income for the period $377,296 $310,492

Net income per common share:

Basic $0.08 $ 0.07

Diluted $0.08 $ 0.07

CASH FLOWS

Provided (used) by:

Operating activities $689,258 $330,684

Investing activities (28,123) (38,125)

Financing activities (1,744,008) (1,113,918)

Decrease in cash $(1,082,873) $(821,359)

BALANCE SHEET

September 30, 2007 June 30, 2007

Cash $881,380 $1,961,712

Total assets 6,611,857 7,987,808

Current liabilities 809,766 819,005

Total liabilities 809,766 819,005

Stockholders' equity $5,802,091 $7,168,803


'/>"/>
SOURCE Unilens Vision Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens
2. Vision restoration therapy shown to improve brain activity in brain injured patients
3. Mouse vision has a rhythm all its own
4. HEI, Inc. Announces Sale of RFID Division Assets
5. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
6. The aye-ayes have it: The preservation of color vision in a creature of the night
7. Can brain-injured, partially-blind stroke patients regain some of their lost vision?
8. HEI, Inc. Closes on Sale of RFID Division Assets
9. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
10. Colorado Medical School Receives Provisional Accreditation
11. Poor Senior Vision Often a Window on Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... 29, 2017 , ... Sterling Global Products is pleased to ... biodegradable, hanging flushable wipes dispensers and/or 42 count refill packs manufactured by this ... Texas, operates more than 350 stores throughout Texas and expanding into northern Mexico ...
(Date:4/29/2017)... ... 29, 2017 , ... Saturday, April 29, marks World Veterinary ... have on animal health and welfare as well as on public health. The ... a theme each year and this year have selected “Antimicrobial Resistance—From Awareness to ...
(Date:4/28/2017)... ... 2017 , ... The National Campaign to Prevent Teen ... to Contraception for Women Servicemembers and Dependents Act of 2017. The bill, introduced ... to ensure that all members of the Armed Forces receive high quality education ...
(Date:4/28/2017)... ... 28, 2017 , ... It's not always common knowledge whether or not a ... unclear as to whether or not they are contagious, and most people don't know ... So, FindaTopDoc took a look into the matter. , They discovered that the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Beginning in 2017, Ridgecrest ... formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure that the ... formula in the following ways:, , Removal of the homeopathic ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... , April 24, 2017 SW Safety ... protection, and comfort, announces the release of the latest ... This most recent example of leading edge nitrile glove ... pattern for 200% more tactile grip on wet and ... and durability. With TracTek and a suite of other ...
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 20, 2017 Research and Markets ... Pipeline and Market Prospects: Addressing Production Complexities Through Risk ... offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities ... in-depth assessment of the current trends in the global ...
Breaking Medicine Technology: